G

ood morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and refreshing, because that ever-demanding routine of meetings, deadlines, and the like has returned. Our routine, however, will be slightly different for the next few days as we bop around the J.P. Morgan Healthcare Conference. Nonetheless, we are still accepting tips and foraging for interesting items. On that note, here are some tidbits. Hope you have a smashing day and do stay in touch …

Teva Pharmaceuticals was chastised by Wall Streeters for lowering its financial guidance once again, “further eroding what, in our view, was already limited management credibility,” according to Piper Jaffray analyst David Amsellem. And he called for a “major” management overhaul after noting the core generics business and brand-name drug business are overdue for a pick-me-up, especially as its all-important Copaxone multiple sclerosis drug faces generic competition.

This is a STAT Plus article and you can unlock it by subscribing to STAT Plus today. It's easy! Your first 30 days are free and if you don't enjoy your subscription you can cancel any time.
Already a subscriber? Log in here.

Leave a Comment

Please enter your name.
Please enter a comment.

  • Stadium food hawkers are hired based on their ability to fling a bag of peanuts across 40 seats to the guy at the end of the row. Now if he can fling the Epipen with the same accuracy he will be promoted.

Sign up for our Morning Rounds newsletter

Your daily dose of news in health and medicine.